» Articles » PMID: 18318825

Virological and Clinical Implication of Core Promoter C1752/V1753 and T1764/G1766 Mutations in Hepatitis B Virus Genotype D Infection in Mongolia

Overview
Specialty Gastroenterology
Date 2008 Mar 6
PMID 18318825
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aim: The aim of the present study was to reveal virological and clinical features of hepatitis B virus (HBV) genotype D infection.

Methods: One hundred and twenty-two Mongolian chronic liver disease (CLD) patients infected with HBV were subjected for serological HBV-markers screening and HBV-enzyme immunoassay (EIA) genotyping. Nucleotide sequences were analyzed for 48 HBV/D strains (23 isolated from hepatocellular carcinoma (HCC) and 25 from CLD patients).

Results: Prevalence of hepatitis B e antigen (HBeAg) positivity was low (25.9%) in young patients (< or =30 years old) indicating early HBeAg seroclearance in HBV/D carriers. The T1764/G1766 double mutation was the most common basal core promoter (BCP) mutation (29.2%) and was frequent in HBeAg-negative patients (39.3%). Patients harboring T1764/G1766 mutants exhibited lower HBV-DNA and HBV core antigen (HBcAg) levels than those with wild-type BCP strains (P = 0.024, 0.049, respectively). C1752 and/or V (not T) 1753 mutation was significantly prevalent in HCC patients (HCC vs CLD; 52.2% vs 20%, P = 0.033). T1762/A1764 mutation was detected in 75.0% of HCC patients with high viral load (> or =5 log copies/mL). Precore stop codon mutation A1896 was detected in (70.8%) of HBV/D-infected patients.

Conclusions: In Mongolians infected with HBV/D, C1752 and/or V1753 mutation was associated with HCC.

Citing Articles

Diversity of HBV genotypes and their association with precore/basal core mutations among HBsAg-positive patients in Ibadan, Nigeria.

Faneye A, Motayo B, Mustafa A, Odiabo G Access Microbiol. 2024; 6(11).

PMID: 39525359 PMC: 11542583. DOI: 10.1099/acmi.0.000821.v3.


Whole genome analysis of hepatitis B virus before and during long-term therapy in chronic infected patients: Molecular characterization, impact on treatment and liver disease progression.

Belaiba Z, Ayouni K, Gdoura M, Kammoun Rebai W, Touzi H, Sadraoui A Front Microbiol. 2022; 13:1020147.

PMID: 36325017 PMC: 9618822. DOI: 10.3389/fmicb.2022.1020147.


Review on hepatitis B virus precore/core promoter mutations and their correlation with genotypes and liver disease severity.

Kumar R World J Hepatol. 2022; 14(4):708-718.

PMID: 35646275 PMC: 9099108. DOI: 10.4254/wjh.v14.i4.708.


Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.

Isabel Gil-Garcia A, Madejon A, Francisco-Recuero I, Lopez-Lopez A, Villafranca E, Romero M World J Gastroenterol. 2019; 25(38):5883-5896.

PMID: 31636479 PMC: 6801187. DOI: 10.3748/wjg.v25.i38.5883.


Hepatitis B virus (HBV) X gene mutations and their association with liver disease progression in HBV-infected patients.

Al-Qahtani A, Al-Anazi M, Nazir N, Ghai R, Abdo A, Sanai F Oncotarget. 2017; 8(62):105115-105125.

PMID: 29285238 PMC: 5739625. DOI: 10.18632/oncotarget.22428.